Research ArticleOpen AccessGoogle Scholar indexed
Rationale and Role of High Loading Dose Clopidogrel in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Accenture Pharmaceutical Services, Bangalore, India
Department of Pharmaceutics Sikkim Manipal University, Bangalore, India
Department of Pharmaceutics, Gautham College of Pharmacy, Bangalore, India
Department of Pharmaceutical Chemistry, Pushpagiri College of Pharmacy, Thiruvalla, Kerala, India
- 1 Accenture Pharmaceutical Services, Bangalore, India
- 2 Department of Pharmaceutics Sikkim Manipal University, Bangalore, India
- 3 Department of Pharmaceutics, Gautham College of Pharmacy, Bangalore, India
- 4 Department of Pharmaceutical Chemistry, Pushpagiri College of Pharmacy, Thiruvalla, Kerala, India
Pharmacology & Pharmacy·Volume 03 (2012)·Pages 481–484·Published 11 October 2012·DOI10.4236/pp.2012.34066
Copy link · social · email
Abstract
Antiplatelet therapy, which reduces platelet activation and aggregation, is the corner stone of treatment for patients undergoing percutaneous coronary intervention (PCI). Clopidogrel is an established oral antiplatelet medication of thienopyridine class, which inhibits blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease. Many studies have revealed that high loading dose clopidogrel in patients undergoing PCI. This review article investigates the rationale and role of high loading dose clopidogrel in patients undergoing PCI.
KeywordsClopidogrelAntiplatelet TherapyPercutaneous Coronary Intervention
- K. Amit and P. C. Christopher, “Acute Coronary Syndromes: Diagnosis and Management, Part I,” Mayo Clin Proc, Vol. 84, 2009, pp. 917-38.
- S. C. Smith, T. E. Feldman and J. W. Hirshfeld, “ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention) ,” Circulation, Vol. 113, 2006, pp. 166-286.
- S. Silber, P. Albertsson and F. F. Aviles, “Guidelines for percutaneous coronary interventions: the Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology,” Eur Heart J, Vol. 26, 2005, pp. 804-847.
- M. D. Quinn, J. Martin, J. Desmond and M. D. Fitzgerald, “Ticlopidine and Clopidogrel,” Circulation, Vol. 100, 1999, pp. 1667-1672.
- S. D. Wiviott, D. Trenk and A. L. Frelinger, “Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation–Thrombolysis in Myocardial Infarction 44 trial,” Circulation, Vol. 116, 2007, pp. 2923-2932.
- Caprie Steering Committee, “A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE),” Lancet, Vol. 348, 1996, pp. 1329–1339.
- S. Yusuf, F. Zhao and S. R. Mehta, “For the Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events (CURE) Trial Investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation,” N Engl J Med, Vol. 345, 2001, pp. 494-502.
- S. R. Mehta, S. Yusuf and R. J. Peters, “Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study,” Lancet, Vol. 358, 2001, pp. 527-533.
- S. B. King, S. C. Smith and J. W. Hirshfeld, “Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,” Vol. 117, No. 6, 2008, pp. 261-295.
- S. R. Steinhubl, P. B. Berger and J. T. Mann, “Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial,” JAMA, Vol. 288, 2002, pp. 2411-2420.